$-0.23 EPS Expected for OncoSec Medical Inc (ONCS)

September 22, 2017 - By Louis Casey

Analysts await OncoSec Medical Inc (NASDAQ:ONCS) to report earnings on October, 12. They expect $-0.23 earnings per share, up 41.03 % or $0.16 from last year’s $-0.39 per share. After $-0.22 actual earnings per share reported by OncoSec Medical Inc for the previous quarter, Wall Street now forecasts 4.55 % negative EPS growth. It closed at $0.98 lastly. It is down 34.57% since September 22, 2016 and is downtrending. It has underperformed by 51.27% the S&P500.

OncoSec Medical Inc (NASDAQ:ONCS) Ratings Coverage

Among 4 analysts covering OncoSec Medical (NASDAQ:ONCS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. OncoSec Medical had 7 analyst reports since March 9, 2016 according to SRatingsIntel. Rodman & Renshaw reinitiated OncoSec Medical Inc (NASDAQ:ONCS) rating on Thursday, July 21. Rodman & Renshaw has “Buy” rating and $6 target. The firm has “Buy” rating by Noble Financial given on Tuesday, June 13. On Friday, June 2 the stock rating was maintained by Maxim Group with “Buy”. H.C. Wainwright maintained the stock with “Buy” rating in Monday, June 12 report. As per Wednesday, March 9, the company rating was maintained by H.C. Wainwright. The rating was maintained by Maxim Group on Thursday, June 8 with “Buy”. H.C. Wainwright maintained OncoSec Medical Inc (NASDAQ:ONCS) rating on Friday, June 2. H.C. Wainwright has “Buy” rating and $600 target.

OncoSec Medical Incorporated is a biotechnology company. The company has market cap of $20.74 million. The Firm is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. It currently has negative earnings. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

More notable recent OncoSec Medical Inc (NASDAQ:ONCS) news were published by: Prnewswire.com which released: “OncoSec Medical’s Intratumoral Plasmid IL-12 Demonstrates Effectiveness at …” on March 21, 2017, also Prnewswire.com with their article: “OncoSec to Host Third Quarter Financial Conference Call on June 1, 2017” published on May 11, 2017, Prnewswire.com published: “OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of …” on September 05, 2017. More interesting news about OncoSec Medical Inc (NASDAQ:ONCS) were released by: Thestreet.com and their article: “Biotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot” published on March 03, 2017 as well as Prnewswire.com‘s news article titled: “OncoSec Medical Appoints Richard B. Slansky as Chief Financial Officer” with publication date: June 25, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com